May 10 |
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
May 10 |
Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results
|
May 9 |
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
|
May 9 |
Crinetics Pharmaceuticals GAAP EPS of -$0.93 misses by $0.13, revenue of $0.6M beats by $0.42M
|
May 9 |
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 8 |
Crinetics Pharmaceuticals Q1 2024 Earnings Preview
|
May 8 |
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
|
May 2 |
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
|
Apr 11 |
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 3 |
Crinetics, Syndax gain amid pitch at Sohn charity conference (update)
|